Medicare drug coverage

Sprycel: 2027 Medicare Part D coverage

27 of 5,495 Part D plans (0%) list Sprycel on their 2027 formulary, the plan's list of covered drugs (down 1 point from 2026). 74% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).

License: a US government work, in the public domain (Public Domain Mark 1.0).

Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.

2027 compared with 2026

Sprycel is number 93 by total Medicare Part D spending in 2024 ($518 million). Plans that list it most often put it on tier 3 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 7 RxNorm products for this name.

Sprycel Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it31 (1%)27 (0%)-1 point
Prior authorization (of plans that list it)31 (100%)20 (74%)-26 points
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)21 (68%)20 (74%)+6 points
Any of the three (of plans that list it)31 (100%)20 (74%)-26 points
Not listed or restricted (of all plans)5,518 (100%)5,488 (100%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

For pharmacies and agencies: check a whole drug list against 2027 formularies.

Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.

For pharmaciesFor agencies

Formulary tier

Sprycel formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 12 (6%)0 (0%)
Tier 30 (0%)21 (78%)
Tier 529 (94%)6 (22%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan IDs are in both files. 0 of them (0%) added prior authorization, step therapy, or a quantity limit for Sprycel, and 8 stopped listing it.

Sprycel: plans in both 2026 and 2027
Plan by planPlans
Same plan ID in both years4,380
Listed it in 2026, not in 20278 (0%)
Listed it in 2027, not in 20261 (0%)
Moved it to a higher tier0 (0%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit0 (0%)
Added at least one of the three0 (0%)
Removed at least one of the three0 (0%)
Plan IDs new in 20271,115
2026 plan IDs not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Sprycel off the formulary or list it with prior authorization, step therapy, or a quantity limit. 49 states tie for the highest share, 100%; Mississippi ranks last at 96%. The table breaks ties on the prior authorization or step therapy share.

States from most to least restrictive for Sprycel, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Massachusetts92100%7%no change
2Pennsylvania324100%4%no change
3New Jersey74100%3%no change
4Alaska9100%0%no change
5Alabama115100%0%no change
6Arizona148100%0%no change
7California397100%0%no change
8Colorado106100%0%no change
9Connecticut54100%0%no change
10District of Columbia21100%0%no change
11Delaware43100%0%no change
12Florida549100%0%no change
13Georgia151100%0%no change
14Hawaii50100%0%no change
15Iowa64100%0%no change
16Idaho45100%0%no change
17Illinois133100%0%no change
18Indiana140100%0%no change
19Kansas84100%0%no change
20Kentucky123100%0%no change
21Louisiana126100%0%no change
22Maryland49100%0%no change
23Maine52100%0%no change
24Michigan183100%0%no change
25Minnesota63100%0%no change
26Missouri171100%0%no change
27Montana27100%0%no change
28North Carolina177100%0%no change
29North Dakota26100%0%no change
30Nebraska51100%0%no change
31New Hampshire25100%0%no change
32New Mexico68100%0%no change
33Nevada100100%0%no change
34New York215100%0%no change
35Ohio173100%0%no change
36Oklahoma81100%0%no change
37Oregon92100%0%no change
38Rhode Island29100%0%no change
39South Carolina91100%0%no change
40South Dakota30100%0%no change
41Tennessee157100%0%no change
42Texas412100%0%no change
43Utah53100%0%no change
44Virginia145100%0%no change
45Vermont14100%0%no change
46Washington114100%0%no change
47Wisconsin97100%0%no change
48West Virginia70100%0%no change
49Wyoming13100%0%no change
50Arkansas8697%0%-3 points
51Mississippi10596%0%-4 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Sprycel off or restrict it.

Sprycel coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
BrightSpring Health Services, Inc.20%none list it100%no change0
Community Health Group20%none list it100%no change0
Community Health Plan of Washington20%none list it100%no change0
Denver Health and Hospital Authority20%none list it100%no change0
Elevance Health, Inc. & BCBSMA & BCBSRI & BCBSVT20%none list it100%no change0
Elite Health Systems, Inc.20%none list it100%no change0
Group Health Cooperative of Eau Claire20%none list it100%no change0
Hamaspik of Rockland County, Inc.20%none list it100%no change0
ISNP Holdings, LLC20%none list it100%no change0
Kansas Superior Select20%none list it100%no change0
Missouri Healthcare Advisors, LLC20%none list it100%no change0
MultiCare Health Systems20%none list it100%new in 20270
NEIGHBORHOOD HEALTH PLAN OF RHODE ISLAND20%none list it100%no change0
PrimeWest Rural MN Health Care Access Initiative20%none list it100%no change0
Regency ISNP Holdings LLC20%none list it100%no change0
Select Founders, LLC20%none list it100%no change0
Sentara Health Care (SHC)20%none list it100%no change0
South Country Health Alliance20%none list it100%no change0
The Regents of the University of California20%none list it100%no change0
Troy Holdings, Inc.20%none list it100%no change0
Associated Care Ventures, Inc.30%none list it100%no change0
Aultman Health Foundation30%none list it100%no change0
Banner Health30%none list it100%no change0
Bexar County Hospital District30%none list it100%no change0
Blue Cross Blue Shield of Nebraska30%none list it100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing